After analysing 13 randomized controlled trials, including data from 3539 patients with EGFR-mutated NSCLC, Holleman et al. showed favourable efficacy of osimertinib in terms of PFS and OS compared to all other EGFR-TKIs [154]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.